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n the late 1990s ethnobotanist Paul Alan Cox visited the in-
digenous Chamorro people of Guam, sleuthing for cancer 
cures in the lush rainforest. He soon stumbled upon trou-
bling facts that would change the trajectory of his career, 
leading  to  major  clues  in  understanding  Lou  Gehrig’s 
disease (amyotrophic lateral sclerosis, or ALS) and possibly other 
neuro  degenerative diseases. Since that time, major breakthroughs in 
the fields of neurobiology, epidemiology, and ecology have led to an 
increased interest in an unlikely hypothesis: that β-methylamino-l-
alanine (BMAA)—a cyanobacterial neurotoxin found in contami-
nated seafood and shellfish, drinking water supplies, and recrea  tional 
waters—may be a major factor in these diseases. 
A Trail of Clues
The trail of clues began soon after U.S. forces recaptured Guam 
from the Japanese in 1944. A Navy neurologist noticed the 
Chamorro people succumbed to a strange neurodegenerative ill-
ness that caused paralysis, shaking, and dementia at 50–100 times 
the incidence of ALS worldwide.
1,2 The illness was dubbed amyo-
trophic lateral sclerosis–parkinsonism/dementia complex (ALS-
PDC), known locally as lytico-bodig. Since then, neurologists have 
converged on the island to crack the medical version of the world’s 
hardest math problem. Solving the mystery of this many-faceted 
illness, it was hoped, could unlock a deeper understanding of 
neuro  degenerative diseases worldwide and possibly lead to a cure.
Last fall, writer Wendee Holtcamp visited Paul Cox’s Institute for EthnoMedicine and Yellowstone National Park’s Grand 
Prismatic Spring, named for the vividly colored cyanobacteria that live along the spring’s edge. She also kayaked on Lake 
Houston to collect water and sediment, which Cox’s group tested for BMAA. The results of that test were described in the 
January/February 2012 issue of Miller-McCune Magazine.55 (Image: dark-field micrograph of the cyanobacterium Nostoc, 
one of the many cyano  bacteria that produce BMAA.)
©
 
M
i
c
h
a
e
l
 
A
b
b
e
y
/
P
h
o
t
o
 
R
e
s
e
a
r
c
h
e
r
s
,
 
I
n
c
.Focus  | The Emerging Science of BMAA
BMAA was first isolated from cycad trees 
on Guam in 1967. The discovery was seren-
dipitous, an offshoot of research on lathy-
rism, a progressive paralysis of the legs found 
in people in China, India, and the Middle 
East. Studies had linked lathyrism to con-
sumption of certain species of legumes that 
contained the compound β-N-oxalylamino-
l-alanine (BOAA).
3 Marjorie Whiting, a 
nutritional anthropologist working on Guam 
for the National Institutes of Health, rec-
ognized a similarity between lathyrism and 
ALS-PDC and asked Arthur Bell, a noted 
plant biochemist and director of the Kew 
Royal Botanic Gardens, to test cycad seeds 
for BOAA. Although the cycads didn’t con-
tain BOAA, Bell discovered a similar com-
pound with a methyl group instead of an 
oxalyl group—BMAA.
4,5 
Subsequent research showed that BMAA 
caused convulsions in chicks
6 and rats
7 and 
damaged rat neurons.
8 However, dietary 
exposure did not cause delayed symptoms 
in rats,
7 whereas ALS-PDC, it soon became 
clear, developed years or even decades after 
exposure ceased. In the 1980s Peter Spencer, 
then a neurotoxicologist at the Albert Ein-
stein College of Medicine, briefly resurrected 
the BMAA hypothesis and reported shaking 
and paralysis in macaques fed BMAA,
9 but 
his work was heavily criticized by another 
team of neurologists that argued that people 
would have to eat kilograms of cycad flour to 
ingest a comparable dose.
10
Cox arrived in Guam in the late 1990s 
after the trail had run cold, but through a 
series of discoveries, he resurrected the dor-
mant hypothesis that BMAA was the cause 
behind ALS-PDC. The Chamorro made 
tortillas out of ground cycad seeds, which 
they washed repeatedly to remove toxins (if 
their chickens didn’t die after drinking the 
wash water, the people deemed the seeds safe 
to grind and eat). They also ate feral pigs 
and fruit bats that fed on cycad seeds—the 
bats, known as Mariana flying foxes, were 
stewed in coconut cream and eaten whole—
brains, bones, skin, and all. In 2002 Cox 
and Columbia University Medical Center 
neurologist Oliver Sacks hypothesized that 
chronic dietary exposure creates a neurotoxic 
reservoir of BMAA in the brain tissues of the 
Chamorros that, after a lag time, leads to a 
neuronal meltdown.
11 The breakthroughs 
that would expand the story beyond Guam 
were soon to come. 
Cox’s colleague Sandra Banack, then a 
biology professor at California State Uni-
versity, Fullerton, was working with Cox 
in Hawaii analyzing Mariana flying fox 
skins to determine whether they contained 
BMAA. “We decided if [BMAA] wasn’t in 
the bats, we’d just move on,” says Cox. In 
a way, Cox says, he hoped BMAA wouldn’t 
be the triggering compound, remembering 
the ridicule encountered by Spencer in the 
1980s. But one night around 2:00 a.m., he 
recalls, “Sandra called me from the lab, and 
I picked up on the first ring. She said, ‘We 
got it.’”
About the same time, Cox and Banack 
made another advance, discovering that 
BMAA was produced by cyanobacteria that 
lived as symbionts in specialized roots of 
the cycads.
12 They tested BMAA in various 
organisms along the food chain and found 
samples of Mariana flying fox skin had exor-
bitant BMAA levels averaging 3,556 µg/g.
13 
This was 10,000 times more than was found 
in free-living cyanobacteria and 3 times as 
much as in the fleshy cycad seed coat eaten 
by the bats, supporting the idea of biomag-
nification (in which a contaminant—usually 
a fat-soluble compound—accumulates in an 
organism).
12 But the biggest surprise came 
when they tested human brains in a blinded 
study. They found high BMAA concentra-
tions not just in the brains of all ALS-PDC 
patients tested but also in the brains of Cana-
dians who died of Alzheimer disease (AD)—
yet not in age-matched controls.
14 If BMAA 
was produced by cyanobacteria on Guam, 
how could people in Canada be exposed? 
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(This page) BMAA is produced by 95% of the genera of cyanobacteria tested, including Nostoc, 
which grows in the roots of the cycad tree and appears as the green lining in the cutaway 
roots pictured above. (Opposite) The seeds of the cycad are used as food and medicine by 
the indigenous Chamorro people of Guam. They are also eaten by bats and feral pigs that are 
consumed by the Chamorro. The resulting heavy dietary intake of BMAA has been linked with 
a constellation of neurodegenerative symptoms known locally as lytico-bodig.Focus  | The Emerging Science of BMAA
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A Cyanobacterial Neurotoxin
Because cyanobacteria photosynthesize, sci-
entists once classified them as algae—and 
many people still refer to them as blue-
green algae—but modern genetics reveals 
a separate evolutionary lineage. Cyanobac-
teria either form symbiotic relationships 
with other organisms or live alone in fresh 
and marine waters, where they can erupt in 
sprawling and often toxic blooms associated 
with high nutrient inputs such as fertilizer 
runoff. They also are found in desert crusts, 
where they spring to life with seasonal rains. 
The incidence of cyanobacterial blooms has 
increased worldwide and may grow even 
more widespread with warming climates.
15 
In a 2005 article in Proceedings of the 
National Academy of Sciences, Cox and sev-
eral colleagues reported testing 30 labora-
tory strains of cyanobacteria and finding 
that 95% of the genera tested produced 
BMAA.
16 “We realized that once we pub-
lished this result, it was going to shake a lot 
of trees,” says Cox. It could mean a para-
digm shift for a field that has invested a 
lot of money studying the genetics of ALS 
rather than environmental triggers. 
Only 5–10% of ALS, AD, and Parkin-
son disease (PD) cases are due to inherited 
genetic mutations, says Walter Bradley, an 
ALS expert and former chairman of neurology 
at the University of Miami Miller School 
of Medicine. “Hundreds of millions of dol-
lars have been spent looking for predispos-
ing genes, but . . . there is really a need to 
concentrate much more on environmental 
toxicants,” Bradley says.
“Big Pharma has spent big money to 
come up with new medications targeted 
against the best mechanisms that the scien-
tific community has tested,” says Deborah 
Mash, a neurologist at the University of 
Miami Miller School of Medicine and 
director of the Miami Brain Bank. Collab-
orating with Bradley, she replicated Cox’s 
brain study, finding BMAA in the brains 
of AD, PD, and ALS victims but not in 
controls.
17 She also showed BMAA crosses 
the blood–brain barrier in rats. In these 
studies, they found that the molecule takes 
longer to get into the brain than into other 
organs, but once there, it gets trapped in 
proteins, forming a reservoir for slow release 
over time.
18,19 
Once Cox realized that BMAA may be 
involved in multiple neurodegenerative dis-
eases, he left Hawaii to establish the Insti-
tute for Ethno  Medicine in Jackson Hole, 
Wyoming, where he was joined by Banack 
and later by James Metcalf, a cyanobacte-
rial expert. While Banack got busy with lab 
work, Cox raised funds for the institute’s 
research and established a loose consortium 
of scientists around the world—epidemiolo-
gists, neurobiologists, and ecologists. They 
meet once a year to discuss research find-
ings and directions for future research. 
Cox has spent the bulk of his research 
efforts focusing on ALS, in part for human-
itarian reasons; ALS strikes healthy, pre-
dominantly middle-aged people seemingly 
at random, and, of the major neurodegen-
erative diseases, it has the least hope for 
treatment and survival (in clinical trials, the 
only FDA-approved treatment
20 for ALS 
offered approximately 3 extra months of 
life, although improved treatment protocols 
may extend this time). 
ALS affects motor neurons, the longest 
cells in the body. Although mental capa-
bilities stay intact, ALS paralyzes patients, 
often from the periphery inward, and most 
patients die within 3 years when they can 
no longer breathe or swallow. At any given 
time, an estimated 30,000 ALS cases exist 
in the United States
21  (compared  with 
5.4 million AD patients
22 and 500,000 PD 
patients
23), but lifetime risk in this country 
is estimated at approximately 1 in 350 for 
men and 1 in 450 for women.
24 Only 10% 
of cases are thought to be inherited (these 
are termed “familial ALS”), with 15–20% 
of these linked to mutation in the SOD1 Focus  | The Emerging Science of BMAA
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(superoxide dismutase) gene.
25 The cause 
of the remaining 90% (termed “sporadic 
ALS”) remains unexplained.
26 
Mistakes in Translation
A foundational aspect of Cox’s hypothesis—
and the part that has proven the most 
contentious
10,27,28,29,30—is that BMAA not 
only occurs as a free, water-soluble molecule 
but also gets bound into proteins. Since 
hydrolysis is necessary to release protein-
bound BMAA,
31 Cox suspects that other 
studies underestimated or missed BMAA 
altogether.
32,33 BMAA is a nonproteinogenic 
amino acid, meaning it is not one of the 
20 amino acids that make up proteins in all 
eukaryotic organisms. 
Accumulation of BMAA in the proteins 
of nerve cells, which need to last a life-
time, would provide a mechanism for how 
the toxin might biomagnify. “The problem 
with neurons is they do not divide, as a gen-
eral rule, so over time they accumulate dam-
aged proteins, and once they reach a critical 
level, it causes the cell to undergo apoptosis 
[cell death],” explains Rachael Dunlop, a 
researcher with the Heart Research Institute 
in Sydney, Australia. 
In rapidly dividing nonneuronal cells, 
Dunlop explains, damaged proteins that 
have formed aggregates are diluted into 
daughter cells. “These cells effectively get 
rid of their ‘junk’ by dilution,” she says. 
“Neuronal cells can’t do that and eventually 
get overwhelmed and die.” Accumulation 
could also explain how BMAA could plau-
sibly lead to the telltale misfolded proteins 
observed in the brains of those who die of 
neurodegenerative disease.
But Cox and colleagues had no addi-
tional conclusive evidence linking BMAA 
and protein aggregates in the brain, and his 
idea came under fire. “The whole scientific 
world at that time thought that the machin-
ery of cells would look at [BMAA] and say, 
‘That’s not one of the twenty [proteinogen-
ic] amino acids,’” says Bradley. Each amino 
acid has its own transfer RNA (tRNA) syn-
thetase, a highly specific enzyme that picks 
up an amino acid and attaches it to the 
matching codon on the messenger RNA 
(mRNA) during translation, an early step 
in the process of protein synthesis. “There 
has been a gradual accumulation of research 
showing that not only does misincorpora-
tion of various nonproteinogenic amino 
acids occur, but it also can cause human 
and animal disease,” Bradley says.
In 2006 Susan Ackerman and colleagues 
published in Nature that misincorporation 
of the wrong proteinogenic amino acid, even 
at the background error rate (1 error per 
1,000–10,000 codons), can lead to neuro-
degeneration in mice.
34 Other research has 
revealed that organisms do, in fact, misin-
corporate nonproteinogenic amino acids.
4,35 
In 2002 Kenneth Rodgers, a senior lecturer 
at the University of Technology, Sydney, 
found that a range of nonproteinogenic 
amino acids can be incorporated into cell 
proteins by mammalian cells, among them 
the amino acid levodopa (l-DOPA), the 
treatment most commonly used for PD.
36 
Rodgers subsequently detected l-DOPA in 
brain proteins of treated PD patients.
37,38 
“We have sequenced proteins and shown 
that l-DOPA is incorporated into proteins 
in place of tyrosine,
39” says Rodgers, who is 
now part of Cox’s consortium.
Evidence that BMAA isn’t just found in 
brain tissue but actually gets misincorpo-
rated into nerve cell proteins and that this 
causes protein misfolding and ultimately 
cell death was presented at the International 
ALS/Motor Neuron Disease (MND) Sym-
posium in December 2011.
40 Rodgers and 
Dunlop reported that the tRNA synthetase 
enzyme for the amino acid serine mistak-
enly picks up BMAA and incorporates it 
into proteins in vitro. Consequent autofluo-
rescence indicated that the proteins mis-
folded, and the cells died.
41 
Multiple Modes of 
Neurotoxicity
In most proteins, the hydrophilic (water-
loving) parts stay on the outside while the 
hydrophobic (water-repelling) parts stay on 
the inside of the structure, but damage or 
mistakes in translation, such as misincorpo-
ration of BMAA, can cause the hydropho-
bic parts of the protein to end up exposed. 
These sticky parts adhere to other mis-
formed proteins, forming “aggregates,” a 
telltale sign of neurodegenerative disease.
42 
The formation of small aggregates seeds the 
formation of larger, more toxic aggregates 
in a sort of chain reaction that prevents the 
cells from functioning effectively.
43
Recent ALS research has focused on 
the role of TAR DNA-binding protein 43 
(TDP-43) in neurodegeneration.
44 “TDP-
43 has been found in protein aggregates 
from patients affected by both familial and 
sporadic forms of ALS, so even without the 
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(Top) The genetic code in the messenger RNA holds the “recipe” for constructing a 
protein, and transfer RNA, which contains the matching code, attaches the correct 
amino acid. New research indicates BMAA can bind to serine (SER) transfer RNA 
and become part of the protein chain.
40 (Bottom) Once BMAA is incorporated into 
the chain, the protein can no longer fold properly. Clumps of misfolded proteins 
may form the aggregates that characterize neurodegenerative disease.
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mutated gene, an improperly functioning 
TDP-43 can contribute to disease,” says 
Dunlop. “If the misincorporation of BMAA 
in place of serine into TDP-43 causes the 
protein to misfold or not function correctly, 
this could contribute to ALS. We are not 
naïve enough to think this is the only cata-
lyst for sporadic ALS—there are likely sev-
eral processes that need to come together 
to lead to motor neuron dysfunction and 
eventually death—but it’s a clue.” 
“The recent finding that BMAA is mis-
taken for serine by tRNA synthetase during 
protein formation opens up a plethora of 
potential new studies in lab models of ALS, 
from yeast to mice, to see whether the for-
mation of protein aggregates—the classic 
‘hallmarks’ of motor neuron degeneration—
can be replicated,” says Brian Dickie, direc-
tor of research at the Motor Neurone Dis-
ease Association. “We held a similar session 
at the 2008 ALS/MND Symposium,
45 and 
I was struck by how many more research 
groups are now working in this field. There 
is definitely greater acceptance that this 
avenue should be pursued.”
In addition to protein misincorpora-
tion, high levels of unbound BMAA can 
continually overstimulate glutamate recep-
tors on cells, leading to neuronal injury.
46 
Marquette University biology profes-
sor Doug Lobner found that BMAA and 
methylmercury—a common pollutant in 
seafood—both deplete glutathione, the 
main endogenous antioxidant in the body, 
and they act synergistically to harm nerve 
cells.
47,48 Depletion of glutathione increases 
free radical damage that is known to occur 
in neurodegenerative diseases and has been 
linked to ALS in a transgenic SOD1 mouse 
model, says Lobner.
49 Because BMAA and 
methylmercury can both turn up in water-
ways, this synergistic action could pose a 
grave problem.
The jury is still out on how multiple 
variables work together to cause neurode-
generation. “There are genetic variables. 
There are environmental variables. There 
are human health variables. This is prob-
ably a smorgasbord of bad things that occur 
to you in your life,” says Mash. “Maybe it’s 
oxidative stress. Maybe it’s BMAA getting 
misincorporated, and you’re building up 
a bunch of junky proteins in the cell. And 
maybe you’re putting stress on the mito-
chondria, and the mitochondria are making 
more reactive oxidative species, and now 
you’ve got a one–two punch on the cell.” 
Other Lines of Inquiry
While the mechanisms of BMAA toxic-
ity are being worked out, ecological work 
has provided other lines of evidence. Mash 
collaborated with algal ecologist Larry Brand 
of the University of Miami Rosenstiel School 
of Marine and Atmospheric Science to test 
for BMAA in sea life from Florida coastal 
waters, including Florida Bay, which has a 
massive recurring cyanobacterial bloom.
50 
Species low on the food chain, including pink 
shrimp and blue crab—both of which are 
eaten by humans—had high BMAA levels, 
comparable to the bat skins from Guam (one 
crab had 6,976 µg/g).
51 Mash’s laboratory has 
also found BMAA in several shark species 
in unpublished research. Brand wants to test 
farm-raised shrimp since, he says, they grow 
in ponds flush with cyanobacteria.
Preliminary data also revealed BMAA 
in dolphin brains.
52 “We’re interested in 
dolphins because they eat the same kind 
of seafood that we do,” says Brand. “I was 
pretty skeptical we’d see anything. From 
a chemical point of view, you really would 
not expect BMAA to biomagnify in the 
food chain.” It turned out 5 of 6 dolphin 
brains sampled contained BMAA; however, 
the cause of death—impact by a boat—was 
known only for the sixth dolphin, which 
had no detectable BMAA in its brain. 
An important area of future research 
involves potential exposure routes in addi-
tion to seafood consumption. Some agricul-
tural fields are irrigated from water bodies 
covered in cyanobacterial blooms, raising the 
potential that BMAA could get into milk, 
meat, or vegetables. Dan Dietrich, a toxicol-
ogy professor at the Universität Konstanz 
in Germany, reported finding unspecified 
large quantities of BMAA in commercially 
available blue-green algae dietary supple-
ments, including Spirulina and Aphanizome-
non flos–aquae,
53 a finding that has not been 
replicated. Cox isolated BMAA from desert 
crusts collected throughout Qatar and sug-
gested that not only might the cyanotoxin 
have contributed to higher rates of ALS in 
Gulf War veterans but also that inhalation 
of BMAA-containing dust could be a con-
cern elsewhere.
54
Drinking water could be a potential 
exposure route, as well. Lake Houston, 
which provides drinking water to Houston, 
Texas, tested positive for BMAA in the 
fall of 2011.
55 A study of the effectiveness 
of water treatment techniques on BMAA 
removal showed that sand filtration, pow-
dered activated carbon, and chlorination 
were effective at removing BMAA—at least 
at the labora tory scale—with flocculation 
less so.
56 No study has tested the effective-
ness of real-world water treatment methods 
at BMAA removal, and at the present time, 
no food or drinking water supplies are test-
ed for BMAA, although Cox suggests that 
monitoring would be prudent.
16 Researchers 
at the Institute for EthnoMedicine recently 
developed an antibody that detects BMAA, 
which they imagine being incorporated into 
a commercial test and a BMAA-removing 
water filter.
Epidemiology provides another impor-
tant line of evidence supporting the BMAA 
hypothesis. Dartmouth-Hitchcock Medical 
Center neurologist Elijah Stommel and col-
leagues used geographic information system 
(GIS) software to map ALS cases and lakes 
with a history of cyanobacterial blooms in 
New Hampshire. They found that people 
living within a half-mile of cyanobacteri-
ally contaminated lakes had a 2.32-times 
greater risk of developing ALS than the 
rest of the population; people around New 
Hampshire’s Lake Mascoma had up to 
a 25 times greater risk of ALS than the 
expected incidence.
57 Although BMAA was 
found in water samples from other lakes, the 
researchers did not detect it in Lake Masco-
ma samples, perhaps, they suggest, because 
of the small amount of cyanobacteria col-
lected on sampling filters. Nevertheless, 
says Stommel, “Our GIS mapping is clearly 
showing clusters in proximity to [harmful 
algal blooms].” He and his team added more 
patients to their database and are preparing 
2 papers for submission in the near future. 
Connecting Dots
Scientists around the world continue to 
research different aspects of the hypothesis. 
Scientists in Sweden found that newborn 
rats treated with BMAA showed early neuro-
toxicity and impaired learning and memory 
as adults.
58 Others are investigating high 
BMAA levels in oysters off the coast of south-
ern France, where an ALS cluster occurs. 
In 2010 the National Toxicology Pro-
gram (NTP) began studies in rat and mouse 
models to determine, among other things, 
whether BMAA accumulates in the brain 
and other tissues and rates of clearance from 
those tissues. If accumulation is demonstrat-
ed, mechanistic studies may be designed to 
further characterize the neurotoxic potential 
of BMAA. Preliminary results from the NTP 
work will be presented at the March 2012 
annual meeting of the Society of Toxicology.
“I don’t know if the BMAA hypothesis 
is true,” says Mash. “I know we’ve measured 
BMAA in the brain, but proximity is not 
causality. You have to have full mechanistic 
underpinnings [to demonstrate causality], 
and that’s going to take a lot of money. It’s 
going to take epidemiologic studies. It’s going 
to take other cell culture models to really 
explain how this could work. And the big 
ticket is going to be environmental studies.”
Among the most promising development 
are 2 drugs on the horizon that may help ALS Focus  | The Emerging Science of BMAA
patients. Cox and colleagues hope to develop 
a drug to potentially stop BMAA from being 
misincorporated, and Adeona Pharmaceu-
ticals has begun Phase II and III clinical tri-
als for a zinc-based drug
59 that has already 
showed promise at slowing ALS progression, 
albeit with a very small sample size.
60
Since many more people may be exposed 
to BMAA than succumb to neurodegenera-
tive diseases, Cox suspects that vulnerabil-
ity may reflect a gene–environment interac-
tion. If BMAA increases the misfolding of 
aggregate-prone proteins such as TDP-43, 
this could represent such a gene–environ-
ment interaction and explain how a single 
environmental factor such as BMAA could 
precipitate ALS-, PD-, and AD-like illness 
that observed on Guam. 
However, no one has yet investigated a 
genetic basis to BMAA vulnerability. In the 
meantime, Cox and colleagues suggest that 
people should take the threat seriously. “We 
encourage water managers to take a closer 
look at cyanobacterial blooms,” he says. 
“We need to encourage places where there 
are commercial shellfish fisheries to pay 
attention to water quality.”
Much work remains to be done. Yet, 
says Bradley, “I don’t think there’s any ques-
tion that the scientific basis of BMAA and 
its neurotoxicity is moving along at a very 
satisfying pace, and it is all concordant with 
the hypothesis.” 
Houston-based freelancer Wendee Holtcamp has written 
for Nature, Scientific American, National Wildlife, and other 
magazines.
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